A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets

Start Date01 Jul 2004

Sponsor / Collaborator

Solvay Pharmaceuticals, Inc.

100 Clinical Results associated with Esterified estrogens/Methyltestosterone

100 Translational Medicine associated with Esterified estrogens/Methyltestosterone

100 Patents (Medical) associated with Esterified estrogens/Methyltestosterone

Literatures (Medical) associated with Esterified estrogens/Methyltestosterone

01 Oct 2024·Toxicon

Unraveling the metabolomic profile and acute toxicity of ethanolic extract from Mimosa tenuiflora (Willd.) Poir. root bark

Article

Author: de Sousa, Renato Pinto ; de Oliveira, Carlos Mario Freitas ; Chaves, Mariana Helena ; Vieira Júnior, Gerardo Magela ; de Freitas Pessoa, Ana Marcia ; Meireles, Victor de Jesus Silva ; Oliveira, André Luiz Ozório ; de Lima Sousa, Rita de Cassia ; Lustosa Barros, Esmeralda Maria ; Ferreira, Jady Vitoria Barjud Pereira ; Leite, Lucas Luan Lima ; Viana Nunes, Adriana Maria ; do Amaral, Maurício Pires de Moura ; Oliveira, Jorge Luiz Silva

Mimosa tenuiflora (Fabaceae) is popularly known in Brazil as "Jurema preta". From the bark of its root, "jurema wine" is obtained, a psychedelic drink used in Indigenous religious rituals in Northeastern Brazil. This work aimed to investigate the chemical composition and acute oral toxicity of the ethanolic extract of the root bark from M. tenuiflora (EEMt). EEMt was analyzed by UPLC-QToF-MS/MS and DI-ESI-IT-MSⁿ. Oral administration of EEMt was performed once at doses of 300 and 2000 mg/kg in female Swiss mice. Signs and symptoms of intoxication, as well as mortality were monitored for 14 days. Thirteen compounds were annotated in EEMt: eight type B proanthocyanidins, three alkaloids, a glycosylated flavonol, and a dihydrochalcone derivative. The acute administration of 300 and 2000 mg/kg of EEMt did not show mortality. It also did not change the food intake or body weight of the animals. However, the relative weights of the kidneys were significantly changed for both doses. Changes in hematological and biochemical parameters were found. In addition, histopathological changes were also observed in the heart, liver, and kidneys. Thus, based on our findings, EEMt presented an LD₅₀ greater than 2000 mg/kg and was therefore classified in category 5 of the Globally Harmonized Classification System (GHS). EEMt showed acute oral toxicity by altering hematological, biochemical and histological parameters.

01 Apr 2011·Food and Chemical ToxicologyQ2 · MEDICINE

Antioxidant and antityrosinase activity of mulberry (Morus alba L.) twigs and root bark

Q2 · MEDICINE

Article

Author: Bor-Sen Wang ; Mei-Ying Wang ; Huo-Mu Tai ; Lee-Wen Chang ; Ming-Hsing Huang ; Wei-Jing Hung ; Lih-Jeng Juang ; Yun-Ju Chen

The antioxidant and antityrosinase activities of the ethanolic extract of mulberry twigs (EEMT) were investigated. The results showed that EEMT exhibited radical scavenging and reducing activity, as well as ferrous ion-chelating activity. In addition, EEMT also protected phospholipids against free radicals, indicating that EEMT could protect biomolecules from oxidative damage. Meanwhile, in the range of 0-60 μg/ml, the tyrosinase inhibitory activity of EEMT increased with increase in sample concentration, and was superior to that of the ethanolic extract of mulberry root bark (EEMR). High-performance liquid chromatography (HPLC) analysis was employed to determine the phenolic components, revealing that maclurin, rutin, isoquercitrin, resveratrol, and morin were present in EEMT. Acting as an antioxidant and a tyrosinase inhibitor, these bioactive constituents could contribute to the protective effects of EEMT. Overall, the results showed that EEMT might serve as a natural antioxidant and tyrosinase inhibitor.

12 Jan 2009·Archives of Internal Medicine

Influence of Estrogen Plus Testosterone Supplementation on Breast Cancer

Article

Author: Jane A. Cauley ; Roberta B. Ness ; Jessica D. Albano ; Anne McTiernan

BACKGROUNDConcern that the use of exogenous testosterone may increase breast cancer risk coexists with rising use of this medication in the United States. We sought to examine the relationship between the use of estrogen plus testosterone (E + T) therapy (esterified estradiol plus methyltestosterone) and the occurrence of breast cancer.METHODSA total of 31,842 postmenopausal participants in the Women's Health Initiative Observational Study were followed for a mean of 4.6 years. At the 3-year visit, E + T users were compared with non-hormone therapy users for time to incident invasive breast cancer. Cox proportional hazards estimates were adjusted for known predictors of breast cancer including prior hormone use and screening mammography.RESULTSThirty five women using E + T at visit 3 developed invasive breast cancer. Use of E + T had a nonsignificant impact on invasive breast cancer risk (adjusted hazard ratio, 1.42; 95% confidence interval, 0.95-2.11). The most commonly used E + T preparation, Estratest, was associated with a significant elevation in invasive breast cancer (adjusted hazard ratio, 1.78; 95% confidence interval, 1.05-3.01). However, rates of breast cancer were lower in longer-term E + T users than in shorter-term E + T users.CONCLUSIONAlthough our results have less strength than an initial report linking E + T to breast cancer, we found a modest, albeit nonsignificant, elevation in breast cancer risk associated with E + T use.

100 Deals associated with Esterified estrogens/Methyltestosterone

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G03EA01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hot Flashes	United States	Solvay SA	-
Menopausal symptoms	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Menopausal symptoms	Phase 2	United States	Solvay Pharmaceuticals, Inc.	01 Jul 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAO2003	Not Applicable	Dry Eye Syndromes postmenopausal women	15	Estratest	(mcziekitcj) = elhmpyjzup vpewplurmz (ddnrjsilmp )	Positive	17 Nov 2003

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Esterified estrogens/Methyltestosterone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation